T.J. Rose

Hey T.J. — congrats on launching Ironleaf. Similar IB → PE background here — been deep in tech-enabled healthcare origination lately. Would be good to connect.

Hey T.J., similar background — though I was doing European growth equity not building a healthcare PE firm like Ironleaf. most funds I talk to have a database — PitchBook or Grata — maybe a CRM, and then the origination setup is mostly Excel and email from there. but the proprietary pipeline doesn't really reflect the effort. everything sits in silos — thesis over here, network over there, data somewhere else — so the off-market stuff never compounds. do you disagree? — Russ

Hey T.J., similar background — though I was doing European growth equity not building a healthcare PE firm like Ironleaf. most funds I talk to have a database — PitchBook or Grata — maybe a CRM, and then the origination setup is mostly Excel and email from there. but the proprietary pipeline doesn't really reflect the effort. everything sits in silos — thesis over here, network over there, data somewhere else — so the off-market stuff never compounds. do you disagree? — Russ

hey T.J. — was thinking about this more. I hit this exact wall doing growth equity — tonnes of data subscriptions, decent CRM, but nothing connecting it all systematically. spent more time stitching than actually originating. imagine Ironleaf has a way more dialled setup — but figured I'd ask. — Russ

hey T.J. — appreciate the connect either way. I'm in and around healthcare tech origination all day — if you ever want to swap notes on what's working, I'm easy to find. — Russ

Hey T.J., see we share a similar PE path, though I was in London doing growth equity not building a healthcare PE firm. most healthcare tech funds I talk to are running on PitchBook or Grata, maybe Affinity, and then basically Excel and email for everything else on the origination side. yet the off-market pipeline stays weirdly thin. the intelligence is all there but it's scattered across tools and inboxes — so nothing compounds into a real origination edge. do you disagree? Russell searchloop.ai linkedin.com/in/russellt23

Hey T.J., was thinking more about origination in tech-enabled healthcare. most funds I talk to are still 70-80% broker-dependent for deal flow. works fine until two funds get shown the same deal and it becomes a pricing war. the proprietary pipeline is the thing that's supposed to prevent that — but it rarely gets built systematically. curious whether Ironleaf has cracked that or if it's the same pattern. Russell searchloop.ai linkedin.com/in/russellt23

hey T.J. — one more thought on this. at my old fund we had a solid stack and smart people, and origination still felt like it restarted from scratch every cycle. took me a while to realise it wasn't a people problem — the tools just didn't talk to each other. always wondered if other healthcare tech funds hit the same thing or if we were just doing it wrong. Russell searchloop.ai linkedin.com/in/russellt23

hey T.J. — been thinking about this a lot — the difference between funds that build origination infrastructure in the first couple of years vs those that keep running on brokers and inbound. by year 3-4 the gap is pretty hard to close. curious if you've been thinking about this at Ironleaf. Russell searchloop.ai linkedin.com/in/russellt23

hey T.J. — no stress on any of this. spend most of my time thinking about origination infrastructure for funds — if that ever becomes a thing worth talking about, I'm around. Russell searchloop.ai linkedin.com/in/russellt23